Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P478: Treatment with ferric maltol associated with improvements in quality of life for IBD patients with iron deficiency anaemiaECCO '18 Vienna
Year: 2018
Authors:

C. Schmidt1,2*, D. Baumgart3, B. Bokemeyer4, C. Büning5, S. Howaldt6, A. Stallmach2, C. Singfield7, G. Tremblay8, T. Jones7

1Klinikum Fulda AG, Medical Clinic II Gastroenterology and Metabolic Disease, Fulda, Germany, 2Jena University Hospital, Clinic for Internal Medicine IV, Jena, Germany, 3Charité Medical Center, Virchow Hospital, Humboldt-University of Berlin, Department of Gastroenterology and Hepatology, Berlin, Germany, 4Gastroenterology Practise Minden, Minden, Germany, 5Waldfriede Hospital, Internal Medicine Department, Berlin, Germany, 6HaFCED e.K., Research Institute for IBD, Hamburg, Germany, 7Shield Therapeutics, London, UK, 8Purple Squirrel Economics, New York, USA

P479: Quality of care and outcomes in a tertiary hospital inflammatory bowel disease (IBD) centre: Monitoring and treatment algorithms during follow-upECCO '18 Vienna
Year: 2018
Authors:

Z. Kurti1*, S. Restellini2,3, L. Gonczi1, W. Afif2, T. Bessissow2, G. Wild2, E. Seidman2, R. Kohen2, A. Bitton2, P.L. Lakatos1,2

1Semmelweis University, First Department of Medicine, Budapest, Hungary, 2McGill University Health Center, Department of Gastroenterology, Montreal, Canada, 3Geneva’s University Hospitals and University of Geneva, Division of Gastroenterology and Hepatology, Geneva, Switzerland

P480: Effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced diarrhoea/colitisECCO '18 Vienna
Year: 2018
Authors:

H. Ibraheim1,2*, M. Samaan1, N. Powell1,2

1Guy's and St Thomas' Hospital, Gastroenterology, London, UK, 2King's College London, School of Immunology and Microbial Sciences, London, UK

P481: Induction treatment with subcutaneous rather than intravenous ustekinumab is associated with comparable circulating drugs levels and early clinical responseECCO '18 Vienna
Year: 2018
Authors:

C.R. Rowan1*, G. Cullen2, H. Mulcahy2, J. Sheridan2,3, E. Ryan4, A. De Vries5, G. D'Haens6, G.A. Doherty2

1St.Vincent's University Hospital, Gastroenterology, Dublin, Ireland, 2St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland, 3University College Dublin, School of Medicine, Dublin, Ireland, 4St.Vincent's University Hospital, Center for Colorectal Disease, Dublin, Ireland, 5Sanquin Blood Supply - Diagnostic Services, Biologicals Laboratory, Amsterdam, The Netherlands, 6Academic Medical Center (AMC), Department of Gastroenterology, Amsterdam, The Netherlands

P482: Transanal minimally invasive proctectomy (TaMIP) in patients with inflammatory bowel diseases (IBD) within the TaTME international databaseECCO '18 Vienna
Year: 2018
Authors:

G. Pellino1,2*, K. Sahnan2,3, M. Penna3,4, S. Adegbola2,3, P. Chandrasinghe2,3,5, A. Spinelli6,7, R. Hompes4, J. Warusavitarne2,3, on behalf of the International TaTME Registry Collaborative

1Università della Campania, Unit of Colorectal Surgery, Naples, Italy, 2St Mark's Hospital, Fistula Research Unit, London, UK, 3Imperial College, Department of Surgery and Cancer, London, UK, 4Oxford University Hospital NHS Trust - Churchill Hospital, Department of Colorectal Surgery, Oxford, UK, 5Faculty of Medicine, University of Kelaniya, Department of Surgery, Kelaniya, Sri Lanka, 6Humanitas University, Colon and Rectal Surgery Unit, Department of General Surgery, Rozzano, Italy, 7Humanitas University, Humanitas University, Department of Biomedical Sciences, Rozzano, Italy

P483: Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Explorative subgroup analyses in IBD from the NOR-SWITCH EXTENSION trialECCO '18 Vienna
Year: 2018
Authors:

K.K. Jørgensen1*, G.L. Goll2, J. Sexton2, I.C. Olsen2,3, N. Bolstad4, K.E. Lundin5,6, I.P. Berset7, E.A. Haavardsholm2,6, C. Mørk8, T.K. Kvien2,6, J. Jahnsen1,6

1Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, 2Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, 3Oslo University Hospital, Research Support Services CTU, Oslo, Norway, 4Oslo University Hospital, Radiumhospitalet, Department of Medical Biochemistry, Oslo, Norway, 5Oslo University Hospital, Rikshospitalet, Department of Gastroenterology, Oslo, Norway, 6University of Oslo, Faculty of Medicine, Oslo, Norway, 7Ålesund Hospital, Department of Gastroenterology, Ålesund, Norway, 8Norwegian University of Science and Technology, Faculty of Medicine, Trondheim, Norway

P484: Infliximab and vedolizumab show a different effect on clot formation in inflammatory bowel disease patientsECCO '18 Vienna
Year: 2018
Authors:

I. Detrez1*, V. Ballet2, M. Peeters1, G. Van Assche2, S. Vermeire2, M. Ferrante2, A. Gils1

1KU Leuven, Leuven, Belgium, 2UZ Leuven, Leuven, Belgium

P485: Real-world evidence (RWE) on outcomes and clinical treatment patterns of 5-aminosalicylic acid (5-ASA) in mild Crohn’s disease (CD) from European healthcare databases (the CROHN’S investigation)ECCO '18 Vienna
Year: 2018
Authors:

K. Paridaens1, Y.L. Yip1, O. Ghatnekar2, M. Plassais1, J. Edwards3, J. Kuiper4, B. Rodgers-Grey3*, S. Buchan3

1Ferring International Center, St-Prex, Switzerland, 2Ferring International PharmaScience Center, Copenhagen, Denmark, 3Strategen Ltd., Basingstoke, UK, 4PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands

P486: Response to vedolizumab therapy in patients with inflammatory bowel disease: Impact of drug levels, anti-drug antibodies and α4β7 target occupancyECCO '18 Vienna
Year: 2018
Authors:

B. Ungar1*, U. Kopylov1, M. Yavzori1, E. Fudim1, O. Picard1, A. Lahat1, D. Coscas1, M. Waterman2, O. Haj-Natour1, N. Orbach-Zingboim1, R. Mao3, M. Chen3, Y. Chowers4, R. Eliakim1, S. Ben-Horin1

1Sheba Medical Center and Sackler School of Medicine, Gastroenterology, Tel Hashomer, Israel, 2Rambam Health Care Campus, Bruce & Ruth Rappaport School of Medicine, Technion Institute of Technology, Department of Gastroenterology, Haifa, Israel, 3The First Affiliated Hospital of Sun-Yatsen University, Guangzhou, China, 4Rambam Health Care Campus and Bruce Rappaport School of Medicine, Technion Institute of Technology, Department of Gastroenterology, Haifa, Israel

P487: Tofacitinib for the treatment of ulcerative colitis: Analysis of infection rates from the OCTAVE clinical programmeECCO '18 Vienna
Year: 2018
Authors:

K.L. Winthrop1, E.V. Loftus Jr.2, D.C. Baumgart3*, W. Reinisch4, A.J. Thorpe5, C.I. Nduaka5, N. Lawendy5, G. Chan5, R.D. Pedersen5, G.S. Friedman5, C. Su5

1Oregon Health and Science University, Portland, OR, USA, 2Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, MN, USA, 3University of Alberta, Division of Gastroenterology, Edmonton, AB, Canada, 4Medical University of Vienna, Department of Internal Medicine III, Vienna, Austria, 5Pfizer Inc., Collegeville, PA, USA

P488: Efficacy of pre-operative oral antibiotic prophylaxis for the prevention of wound infections in patients with Crohn's diseaseECCO '18 Vienna
Year: 2018
Authors:

M. Uchino*, H. Ikeuchi, T. Bando, T. Chohno, H. Sasaki, Y. Horio, R. Kuwahara, T. MInagawa

Hyogo College of Medicine, Inflammatory Bowel Disease, Nishinomiya, Japan

P489: Clinical experience with ustekinumab in selected Crohn's disease patientsECCO '18 Vienna
Year: 2018
Authors:

S. Saman*, T. Klag, J. Wendler, M. Goetz, N.P. Malek, J. Wehkamp

University Hospital Tuebingen, Gastroenterology, Tuebingen, Germany

P490: Drug survival and immunogenicity after switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: Two-year follow-up of a prospective observational cohort studyECCO '18 Vienna
Year: 2018
Authors:

L. Smits1*, L. Derikx1,2, A. van Esch1, J. Drenth1, R. Boshuizen3, D. de Jong1, F. Hoentjen1

1Radboud University Medical Centre, Gastroenterology and Hepatology, Nijmegen, The Netherlands, 2Jeroen Bosch Hospital, Gastroenterology and Hepatology, Hertogenbosch, The Netherlands, 3Sanquin Diagnostic Services, Biologics Laboratory, Amsterdam, The Netherlands

P491: Comparative efficacy on mucosal healing of pharmacological therapies for moderate-to-severe ulcerative colitis, based on prior exposure to tumour necrosis factor antagonists: A systematic review and network meta-analysisECCO '18 Vienna
Year: 2018
Authors:

P. Paschos1,2, A. Katsoula3, O. Giouleme3*, A. Tsapas1,4

1Aristotle University, Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Thessaloniki, Greece, 2“Papageorgiou” Hospital, 1st Department of Internal Medicine, Thessaloniki, Greece, 3Aristotle University, Second Propedeutic Medical Department, Thessaloniki, Greece, 4University of Oxford, Harris Manchester College, Oxford, UK

P492: Gender differences in patient’s perspectives for impact of inflammatory bowel disease on their life: An Online Korean Association for the Study of Intestinal Disease (KASID) surveyECCO '18 Vienna
Year: 2018
Authors:

Y.S. Kim1*, G.S. Seo2, S.W. Hwang3, H.J. Yang4, C.H. Tae5, H.J. Lee6, D.-w.L. Lee7, Y.J. Lee8, D.-S. Myung9, J.M. Lee10, Y.T. Jeen11

1Seoul National University Hospital Gangnam Center, Internal Medicine, Seoul, South Korea, 2Wongkwang University Hospital, Internal Medicine, Iksan, South Korea, 3University of Ulsan College of Medicine, Internal Medicine, Seoul, South Korea, 4Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Internal Medicine, Seoul, South Korea, 5College of Medicine, Ewha Womans University, Internal Medicine, Seoul, South Korea, 6Seoul National University Hospital, Internal Medicine, Seoul, South Korea, 7Korea University Ansan Hospital, Internal Medicine, Ansan-si, South Korea, 8Keimyung University School of Medicine, Internal Medicine, Daegu, South Korea, 9Chonnam National University Medical School, Internal Medicine, Gwangju, South Korea, 10St. Vincent's Hospital, Internal Medicine, Suwon, South Korea, 11Korea University Hospital, Internal Medicine, Seoul, South Korea

P493: Comparison of the efficacy of infliximab biosimilar (Remsima®) vs. infliximab original (Remicade®) in patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

M.F. Guerra Veloz1*, M. Belvis Jimenez1, T. Valdes Delgado1, R. Perea Amarillo1, L. Castro Laria1, B. Maldonado Pérez1, V. Merino2, A. Benítez Roldán1, A. Caunedo Álvarez1, F. Argüelles-Arias1

1Virgen Macarena Hospital, Gastroenterology, Sevilla, Spain, 2Virgen Macarena Hospital, Pharmacy Unit, Sevilla, Spain

P494: Monocytic TNF production predicts response to infliximab treatment in Crohn’s disease but not ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

B. Jessen1,2*, D. Lissner1, E. Sonnenberg1, M. Schumann1, F. Schmidt1, A. Kühl1, B. Siegmund1

1Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Department for Medicine (Gastroenterology, Infectious diseases, Rheumatology), Berlin, Germany, 2Berlin Institute of Health, Berlin, Germany

P495: Does drug level monitoring help us to understand the mechanism behind the superiority of combo therapy in inflammatory bowel diseases?ECCO '18 Vienna
Year: 2018
Authors:

A. Fábián1*, K. Szántó1, A.L. Szíjártó2, R. Bor1, A. Bálint1, K. Farkas1, Á. Milassin1, M. Rutka1, Z. Szepes1, I. Földesi3, D. Kata3, Z.A. Mezei4, S. Lovas5, K. Palatka5, T. Molnár1

1University of Szeged, First Department of Medicine, Szeged, Hungary, 2University of Szeged, Department of Medical Physics and Informatics, Szeged, Hungary, 3Institute of Laboratory Medicine, Szeged, Hungary, 4University of Debrecen Clinical Center, Department of Laboratory Medicine, Debrecen, Hungary, 5University of Debrecen, 2nd Department of Internal Medicine, Debrecen, Hungary

P496: Real-world outcomes of vedolizumab for inflammatory bowel disease post liver transplantationECCO '18 Vienna
Year: 2018
Authors:

M. Peverelle*, C. Mills, A. Testro, P. de Cruz

Austin Health, Gastroenterology and Hepatology, Melbourne, Australia

P497: Injection site reactions and injection site pain for the adalimumab biosimilar ABP 501: Results from two double-blind, randomised, controlled studiesECCO '18 Vienna
Year: 2018
Authors:

E. Krishnan*, N. Zhang, H. Wang

Amgen Inc., Biosimilars, Thousand Oaks, USA